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Juvenile myelomonocytic leukemia (JMML) is a rare childhood leukemia that has histori-
cally been very difficult to confidently diagnose and treat.The majority of patients ultimately
require allogeneic hematopoietic cell transplantation (HCT) for cure. Recent advances in
the understanding of the pathogenesis of the disease now permit over 90% of patients
to be molecularly characterized. Pre-HCT management of patients with JMML is currently
symptom-driven. However, evaluation of potential high-risk clinical and molecular features
will determine which patients could benefit from pre-HCT chemotherapy and/or local con-
trol of splenic disease. Furthermore, new techniques to quantify minimal residual disease
burden will determine whether pre-HCT response to chemotherapy is beneficial for long-
term disease-free survival. The optimal approach to HCT for JMML is unclear, with high
relapse rates regardless of conditioning intensity. An ongoing clinical trial in the Children’s
Oncology Group will test if less toxic approaches can be equally effective, thereby shift-
ing the focus to post-HCT immunomanipulation strategies to achieve long-term disease
control. Finally, our unraveling of the molecular basis of JMML is beginning to identify pos-
sible targets for selective therapeutic interventions, either pre- or post-HCT, an approach
which may ultimately provide the best opportunity to improve outcomes for this aggressive
disease.
Keywords: juvenile myelomonocytic leukemia, chemotherapy, splenectomy, hematopoietic cell transplantation,
immunotherapy, minimal residual disease
INTRODUCTION
Juvenile myelomonocytic leukemia (JMML) is an uncommon
overlap myeloproliferative/myelodysplastic neoplasm that occurs
exclusively in young children, with a median age of diagno-
sis of <2 years (1, 2). Patients frequently present with a high
disease burden and severe clinical symptoms, including massive
hepatosplenomegaly, pulmonary infiltrates, fevers, infections, and
rash (3). With few exceptions, long-term event-free survival (EFS)
has only been achieved following hematopoietic cell transplan-
tation (HCT) (4). However, the optimal therapeutic regimen,
both before and during the HCT process, has yet to be identi-
fied, and large-series published 5-year overall survival (OS) rates
range between 52 and 64% (1, 2).
ESTABLISHING THE DIAGNOSIS
The clinical picture of JMML can be somewhat non-specific,
and until very recently most children with JMML were diag-
nosed solely upon meeting a certain number of clinical features,
such as splenomegaly (present in >90% of cases at diagnosis),
a white blood cell count >10,000/µL with circulating immature
myeloid forms, an absolute monocyte count (AMC) >1000/µL,
increased fetal hemoglobin for age, <20% blasts, and absent
BCR/ABL fusion gene (Table 1) (5). Diagnostic confirmation can
be enhanced via identification of one of the hallmark features
of JMML, such as hypersensitivity of myeloid progenitor cells to
the cytokine granulocyte macrophage colony stimulating factor
(GM-CSF) in methylcellulose assays (6), which is currently avail-
able in only a few CLIA-approved laboratories. GM-CSF-mediated
hyperphosphorylation of STAT5 protein in phosphoflow cytome-
try assays (7, 8) promises to be an exciting technique, but remains
currently a research test only.
Fortunately, deciphering the genetic underpinnings of JMML
has facilitated molecular approaches to diagnosis. The associa-
tion between JMML and certain inherited syndromes advanced
understanding of both disorders. For example, the incidence of
JMML is increased 200- to 500-fold in neurofibromatosis type
1 (NF1) (9). NF1 encodes neurofibromin, a GTPase activating
protein (GAP) for Ras, which negatively regulates Ras output
(10). Studies of human JMML specimens and gene-targeted mice
show that NF1 acts as a tumor suppressor in myeloproliferative
neoplasms and leukemogenesis by inhibiting Ras signaling (11,
12). Noonan syndrome (NS) is characterized by multiple devel-
opmental defects, and some patients develop a transient MPN
(13, 14). The discovery of germline missense mutations in the
PTPN11 gene in ~50% of NS patients (15) proved critical for
understanding the associated transient MPN and led to the dis-
covery that somatic PTPN11 mutations are the most common
cause of JMML (16, 17). Our recent discovery of homozygous
CBL mutations in JMML led to further investigations demonstrat-
ing that such lesions are usually heterozygous germline events with
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Table 1 | Juvenile myelomonocytic leukemia diagnostic criteriaa.
Category 1 Category 2 Category 3
All of the following At least one of the
following
At least two of the
following
• Splenomegalyb
• Absolute monocyte
count (AMC)
>1000/µL
• Blasts in PB/BM
<20%
• Absence of the
t(9;22) BCR/ABL
fusion gene
• Somatic mutation in
RAS or PTPN11
• Clinical diagnosis of
NF1 or NF1 gene
mutation
• Homozygous
mutation in CBL
• Monosomy 7
• Circulating myeloid
precursors
• WBC >10,000/µL
• Increased fetal
hemoglobin (Hgb F)
for age
• Clonal cytogenetic
abnormality excluding
monosomy 7
• GM-CSF
hypersensitivity
The diagnosis of JMML is made if a patient meets all of the Category 1 criteria
and one of the Category 2 criteria without needing to meet the Category 3 crite-
ria. If there are no Category 2 criteria met, then the Category 3 criteria must be
met.
aModified from Chan et al. (5).
bFor 7–10% of patients without splenomegaly, the diagnostic criteria must include
all other features in Category 1 and one of the parameters in Category 2, or no
features in Category 2 but two features in Category 3.
somatic loss of heterozygosity in the hematopoietic compartment,
similar to what happens in NF1-mutated JMML (18). In addi-
tion, somatic NRAS and KRAS mutations occur in approximately
equal frequencies in patients with JMML and led to the interest-
ing observation that some patients with NS harbor germline RAS
lesions, albeit in alternative codons (19, 20). In total, 85–90% of
patients with de novo JMML harbor mutations in genes that reg-
ulate the Ras pathway: PTPN11 35%, NRAS/KRAS 30%, NF1 loss
10–15% [reviewed in Ref. (21)], homozygous CBL 10% (18, 22).
Mice with similar mutations in Nf1, Kras, Ptpn11, and Cbl, all
develop fatal MPN resembling JMML (23–28). Other mutations
that have been reported to occur less frequently in JMML include
ASXL1 and FLT3 (29, 30). Recent whole exome strategies have
also identified mutations in SETBP1 and JAK3 occurring in up to
16% of JMML patients, and confer a poorer prognosis, though the
therapies delivered were variable (31).
Therefore, we can now molecularly confirm the diagnosis of
JMML in approximately over 90% of patients. In the remain-
ing patients, other classic JMML features, such as the presence of
monosomy 7, can support the diagnosis. In the absence of being
definitively diagnosed with JMML, other diseases should be con-
sidered, such as Wiskott–Aldrich Syndrome (32) or neonatal CMV
infection (33). Unfortunately, due to the rarity of the diagnosis
and the relatively recent discovery of pathogenic mutations, it is
difficult to determine the prognostic significance of any one of
these alterations. Indeed, the majority of published studies have
included patient outcomes without molecular confirmation of the
disease. The newest generation of trials, however, will include cen-
tral molecular diagnosis, and will also allow analysis of potential
differences between the various genetic subgroups in terms of
responses to therapy, as some small studies have suggested that
patients withPTPN11mutations may have less favorable outcomes
(34–36).
The overlap between somatic alterations and germline syn-
dromes has important implications on whether or not to per-
form a HCT. As stated above, it has long been recognized that
patients with NF1 who develop full-blown JMML require HCT
for cure. Conversely, patients with germline mutations in PTPN11
(NS) develop a myeloproliferative disorder that strongly resembles
JMML, though nearly all cases appear to spontaneously regress
over the first 18 months of life without a need for HCT (14, 37).
These patients typically have characteristic findings upon physical
examination, and also have codon substitutions that are largely
confined to patients with NS, as opposed to the spectrum of
somatic lesions that occur in de novo JMML. Simultaneous testing
of a buccal swab sample can help confirm or rule out NS. Recently,
germline mutations in NRAS have also been shown to cause some
cases of NS (38) and spontaneous regression of JMML (39). Inter-
estingly, it has even been reported that some patients with somatic
NRAS (especially the NRASG12S) (40) and KRAS (especially the
KRASG12V) (41) mutations, may have an indolent course or even
spontaneously regress their MPN. Finally, it appears that most
patients with JMML due to CBL mutations have a germline muta-
tion, either inherited in an autosomal dominant fashion or arising
from a spontaneous germline event, with acquired uniparental
isodisomy in the leukemic cells. This is often associated with
characteristic clinical features, such as café-au-lait spots, juvenile
xanthogranulomas, male cryptorchidism, hearing loss, and growth
and developmental delay (18). Some patients with CBL mutations
can have aggressive JMML, while others appear to spontaneously
resolve, only to go on later to develop significant, and sometimes
fatal, vasculitis (18). This vasculitis does not appear to be seen in
patients who undergo HCT, such that we are still recommending
HCT for patients withCBL mutations who demonstrate an aggres-
sive clinical course, at least until we have a better understanding
of why certain patients spontaneously improve.
RISK-STRATIFICATION
To date, there has not been a rigorous development of a risk-
stratification system for patients with JMML either at time of diag-
nosis (to guide potential administration of pre-HCT chemother-
apy), or at time of HCT (to guide post-HCT interventions).
Various factors have been identified that contribute to poor out-
comes (Table 2) (1, 2, 34, 36, 42), though these have not always
been replicated between studies. Limited gene-expression profil-
ing and DNA hypermethylation studies have identified signatures
that are prognostic of poor outcome and appear independent of
genotype (36, 43). As molecular diagnosis improves and new labo-
ratory techniques become available, a major aim of future studies
will be the development of a genomics-based risk-stratification
system.
Patients with JMML who transform into AML (currently
defined as >20% blasts in bone marrow) generally have dismal
outcomes following HCT. As noted above, there was a 0% EFS
rate in EWOG-MDS/EBMT trial for patients who entered HCT
with>20% blasts (1). Data are relatively lacking on whether these
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Table 2 | Juvenile myelomonocytic leukemia high-risk features.
EWOG/EBMT EUROCORD/
CIBMTR
UK Europe Japan Conclusion
Number studied (N ) 100 (1) 110 (2) 67 (42) 44 (36) 71 (34)
HOST FACTORS
Age at diagnosis (years) >4 >1.4 >2 >2 >2 Older age is high-risk, best cut-off
age has not been defined
Gender Female Not seen Not reported Not seen Not seen Evidence inconclusive
JMML-SPECIFIC FACTORSc
Type of mutation Not seen Not seen Not reported PTPN11 (trend) PTPN11 PTPN11 may be high-risk
Cytogenetic abnormality Not seen Monosomy 7 Not monosomy 7 Monosomy 7 “Abnormal” Monosomy 7 likely high-risk,
evidence conflicting
HgbF at diagnosis >40% Not seen Elevated Not seen Not seen >40% may be high-risk
Platelet count at diagnosis Not seen Not seen <40×109/L Not seen Not seen Low platelets may be high-risk
BM blasts at HCT >20% Not seena Not reported Not seenb Not reported >20% blasts is probably high-risk
TREATMENT-RELATED FACTORS
Splenectomy Not seen Beneficial Not reported Not reported Not reported Debatable, benefit may be specific
to UCBT
Pre-HCT AML-like chemo Not seen Beneficial Not reported Not reported Not reported Debatable, benefit may be specific
to UCBT
HLA well-matched donor Not seen Beneficial Not reported Not seen Not reported Debatable, benefit may be specific
to UCBT
Serotherapy Beneficial Not seen Not reported Not reported Not reported Debatable, benefit may be specific
to non-UCBT
aPatients with >20% blasts at HCT not included.
bAML-like gene-expression profile is highest-risk.
cDNA hypermethylation is also high-risk (44).
poor outcomes also apply to those who at any point pre-HCT had
evidence of AML transformation. However, gene-expression pro-
filing techniques can distinguish a population of “typical” JMML
patients (with a 10-year EFS rate of 63%) vs. those with an AML-
like pattern (with a 10-year EFS rate of 6%) (36). Given these
dismal outcomes, it would be reasonable to consider patients with
AML transformed out of JMML for experimental therapies prior
to HCT.
PRE-HCT TREATMENT
A variety of pre-HCT treatments have been employed to con-
trol symptoms of JMML (such as organomegaly and pulmonary
problems) as well as theoretically improve outcomes. A common
treatment is the use of oral 6-mercaptopurine (50 mg/m2/day),
sometimes combined with cis-retinoic acid (100 mg/m2/day)
(45). Low-dose intravenous cytarabine (40 mg/m2/day× 5 days)
administration has also been used, as has the combination
of high-dose cytarabine (2 g/m2/day× 5 days) plus fludarabine
(30 mg/m2/day× 5 days) (46). Pulmonary rebound phenomena
can occur after such therapies are delivered and as such, patients
need to have careful monitoring during their recovery phase (C.
Niemeyer, personal communication). However, to date no study
has conclusively demonstrated a benefit of pre-HCT treatment in
post-HCT survival outcomes.
THE ROLE OF PRE-HCT MYELOSUPPRESSIVE
CHEMOTHERAPY
The EWOG-MDS/EBMT trial showed that patients who had no
therapy or low-dose chemotherapy compared to high-dose AML-
like chemotherapy, had nearly identical rates of 5-year EFS (52
vs. 50%), relapse incidence (35 vs. 38%), and transplant-related
mortality (13 vs. 13%) (1). The grouping of patients who got
no chemotherapy with those that got low-dose chemotherapy
makes it difficult to determine if there is any benefit to low-
dose chemotherapy. Furthermore, it is challenging to interpret
this data, as the choice of pre-HCT chemotherapy was left to the
treating physician’s discretion, and patients with higher disease
burdens were likely more intensively pre-treated. A significant
number (10%) of patients on this trial had AML transformed
out of JMML at time of HCT, and they had a 0% EFS rate. It
stands to reason that these were the patients most likely to have
previously received AML-like chemotherapy, and therefore may
have obscured a potential benefit to intensive chemotherapy in a
“standard” patient with JMML.
In the EUROCORD/CIBMTR retrospective study, which
specifically excluded patients with >20% blasts at time of umbil-
ical cord blood transplant (UCBT), there seemed to be improved
EFS in patients who got AML-like therapy compared to none or
low-dose chemotherapy (55 vs. 32%; P = 0.048) (2). Interestingly,
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this improvement in survival did not correlate with post-HCT
relapse, but rather with decreased TRM in those who got AML-
like chemotherapy (20 vs. 43%; P = 0.01). TRM in this study
was multi-factorial, including 50% from infections, 17% from
organ failure, 17% GVHD, 13% rejection, and 4% hemorrhage.
No explanations were offered for this paradoxical finding, but
possible hypotheses for a benefit of AML-like chemotherapy
on TRM could include: (1) decreased rejection via enhanced
immunosuppression and/or smaller spleen sizes; (2) faster count
recovery due to smaller spleen sizes resulting in less infec-
tions and bleeding; or (3) a component of tumor lysis syn-
drome during conditioning contributing to organ failure post-
HCT. Whether this is an effect specific to UCBT remains to
be seen.
Furthermore, these studies only report on whether or not AML-
like chemotherapy was utilized, but do not carefully distinguish
on whether or not there was a response to that chemotherapy.
This is due to the fact that historically measuring responses in
patients with JMML has been exceptionally difficult, using only
relatively crude measures such as WBC count, BM blast percent-
age, and spleen size at time of HCT (46). Fortunately, the same
technology utilized to detect the diagnostic mutation can now be
used to measure disease burden down to minimal amounts of
residual disease for patients with mutations in PTPN11, NRAS,
KRAS, and CBL (47). Therefore, future studies will be able to dis-
tinguish whether response to chemotherapy vs. simply the use
of chemotherapy, prior to HCT impacts on post-HCT relapse
and survival.
THE ROLE OF PRE-HCT-TARGETED CHEMOTHERAPY
Given the current lack of convincing evidence for traditional
myelosuppressive chemotherapy pre-HCT, as well as data to sup-
port hyperactive Ras/MAPK signaling in JMML, there has been
significant attention directed toward developing novel-targeted
therapeutics for patients with JMML. In particular, inhibition
of signaling through the Ras/MAPK pathway has shown benefit
in primary human cells, genetically engineered mouse models of
JMML, and induced pluri-potent stem cells (44, 48–50). Together,
the data have supported development of early phase clinical trials
using MEK inhibitors for JMML. Unfortunately, the therapeutic
promise of inhibiting Ras farnesylation has not been borne out
in numerous studies of other myeloid malignancies, likely due
to an alternative mechanism of activation of Ras via geranylger-
anylation. Indeed, outcomes for JMML patients treated with a
window of Zarnestra, a farnesyl-transferase inhibitor, was actually
worse than patients who did not receive treatment with Zarnes-
tra, though reasons for this are unclear (A. Ward, unpublished
data). Recent reports of aberrant DNA methylation contributing
to increased risk of relapse (43) has led to a European proto-
col to employ DNA hypomethylating agents such as 5-azacitidine
for therapy. To date, this strategy has only been published in
a single patient with a monosomy 7 and a KRAS mutation.
Over an 18-month timespan, an excellent clinical (resolution
of organomegaly, monocytosis, thrombocytopenia, and mono-
somy 7) and molecular response (disappearance of mutantKRAS)
was noted in this patient which may have facilitated successful
HCT (51).
THE ROLE OF SPLENECTOMY
Pre-transplant splenectomy for patients with JMML is controver-
sial, especially given the long-term risks associated with this proce-
dure (52) and lack of conclusive benefit. The EWOG-MDS/EBMT
JMML trial demonstrated that a comparison of children with: (1)
a spleen size <5 cm at HCT; or (2) spleen >5 cm at HCT; or (3)
post-splenectomy at HCT, showed no statistical benefit in EFS (5-
year EFS; 61 vs. 44 vs. 48%, respectively), relapse incidence (5-year
RI; 24 vs. 45 vs. 39%, respectively), or treatment-related mortality
(5-year TRM; 15 vs. 11 vs. 13%, respectively) (1). However, in the
EUROCORD/CIBMTR study, there was a trend toward an EFS
benefit for splenectomy (56 vs. 36%; P = 0.098) (2). These two
findings are not mutually exclusive, as an enlarged spleen at the
time of an HCT with smaller cell doses (such as is seen in UCBT)
may interfere with a successful engraftment or count recovery,
and therefore be associated with more deaths from either TRM
or relapse. If pre-HCT chemotherapy fails to adequately reduce
splenic size, one theoretical solution would be to provide focal
splenic irradiation. There is no published experience with this
strategy in patients with JMML, but in a large number of adults
with CML, MDS, or myeloproliferative disease, when employed in
low doses (median of 900 cGy) immediately prior to HCT (UCBT
excluded), splenic irradiation had no benefit (53). However, it
remains unclear in patients with JMML whether a higher dose of
splenic irradiation (a biologically effective dose of up to 20 cGy
can be delivered without permanent splenic dysfunction) (54) at
an earlier time from HCT (to allow for effective alteration of the
degree of splenic migration) would play a role in splenic shrink-
age and hence either relapse prevention or improved engraftment,
especially in those receiving UCBTs.
APPROACHES TO HCT
Outcomes of HCT for JMML remain sub-optimal. For 100 patients
transplanted primarily with sibling or adult bone marrow from
1993 to 2002 in 29 European centers, the 5-year EFS was only 52%,
with a 5-year OS of 64%. Focusing exclusively on 110 patients who
received UCBTs from 1995 to 2010, the 5-year EFS and OS rates
were 44 and 52%, demonstrating a lack of significant improvement
over time in outcomes other than TRM.
CONDITIONING REGIMEN AND THE TRANSPLANT PROCESS
Only one trial with a large number of JMML patients given a
uniform conditioning regimen has been published to date. The
EWOG-MDS/EBMT trial utilized myeloablative doses of busulfan
(16–20 mg/kg orally over 4 days,a minority with pharmacokinetic-
directed targeting to achieve a concentration steady state of
500–800 ng/mL), plus cyclophosphamide (120 mg/kg over 2 days),
and melphalan (140 mg/m2 once) (BU–CY–MEL). One small
report of 10 children given busulfan (560 mg/m2 orally over
4 days), plus fludarabine (120 mg/m2), and melphalan (180–
210 mg/m2) demonstrated promising results with 7 patients in
remission >2 years since HCT (55). The COG AAML0122 trial
employed a phase II window of a farnesyl-transferase inhibitor
followed by conventional moderate dose AML-type chemother-
apy and cis-retinoic acid. Conditioning utilized cyclophosphamide
(120 mg/kg over 2 days) and 1200 cGy total body irradiation (TBI),
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but compliance was poor with the intended TBI regimen, par-
ticularly after the busulfan-based EWOG-MDS/EBMT trial was
published. Given the young-age at HCT (2.2–2.5 years) of most
patients with JMML (1, 2), it would generally be preferable to avoid
TBI-based regimens in order to avoid long-term endocrinologic
and neurocognitive damage.
Furthermore, despite this escalation in regimen intensity to
something approaching the maximal end of the tolerability spec-
trum, relapse rates remain very high, and limited progress is being
made. The EWOG-MDS/EBMT trial published in 2005 included
100 patients transplanted from 1993 to 2002, with a 5-year OS
of 64% (1). The EUROCORD/CIBMTR retrospective study pub-
lished in 2013 included 110 patients transplanted from 1995 to
2010 (with a median year of 2003), during which time advances
in HLA-matching and supportive care techniques significantly
improved the TRM rates of patients undergoing unrelated donor
HCT (56). However, despite these advances, the 5-year OS for the
EUROCORD/CIBMTR retrospective study was only 52% (2).
Therefore, further dose escalations are unlikely to be benefi-
cial, and indeed, the modern trend in allogeneic HCT has been
to de-escalate conditioning intensity slightly in order to mini-
mize toxicities. As long as the regimen is still within the realm
of myeloablation and successfully achieves donor cell engraft-
ment, it is reasonable to expect that the alloreactive process can
be established with long-term control of disease. In fact, there
are several retrospective studies that suggest that the relapse inci-
dence for adult patients with AML/MDS is at least comparable
(and potentially favors) busulfan plus fludarabine (BU–FLU) over
busulfan–cyclophosphamide (BU–CY) (57, 58). The one excep-
tion to the intensity-rule is a randomized trial for patients with
AML, where TBI was intensified from 1200 to 1575 cGy, and found
that relapse rates were lower, with no benefit to survival due to
increased toxicity (59). Furthermore, the acute GVHD rates were
higher in the 1575-cGy group, suggesting that the relapse pro-
tection may not be from a direct anti-leukemic effect, but rather
from induction of increased alloreactivity. Similar concerns were
recently raised regarding the benefit of melphalan in the condi-
tioning regimen of children with JMML and MDS, where patients
who non-randomly received BU–CY alone had less aGVHD of the
gastrointestinal tract than those who received BU–CY–MEL, with
at least equivalent OS rates (60).
Taking this one step further, another group has non-randomly
compared BU–FLU (160 mg/m2 over 4 days) to BU–CY–MEL in a
mixed group of pediatric patients, and found decreased toxicity
with equivalent survival (61). In conjunction with the knowl-
edge that no amount of chemotherapy is curative for the standard
patient with JMML, these findings call into question the entire
strategy of maximally intense conditioning for JMML. An alterna-
tive hypothesis is that the sole purpose of the conditioning regimen
is to reliably and safely establish donor cell engraftment and pro-
vide a platform for donor alloreactivity to perform the actual
disease control. This hypothesis is being prospectively tested in
the ongoing COG trial, ASCT1221: a randomized phase II study
comparing two different conditioning regimens prior to allogeneic
HCT for children with JMML (NCT01824693).
Some other lessons applicable to the HCT process for JMML
can be learned via careful evaluation of the published data. First,
univariate analysis revealed that TRM was lower (6 vs. 22%;
P = 0.035) when a male donor was utilized (1). This likely is a
reflection of the male predominance of the disease, but highlights
the importance of careful donor selection. Furthermore, there was
no detriment to longer intervals between diagnosis and HCT for
EFS, relapse, or TRM, suggesting that there is time to perform a
careful and complete donor search (1). Finally, for UCBT, units
with 0–1 HLA disparity resulted in a trend toward improved EFS
than those with 2–3 HLA disparities (48 vs. 34%; P = 0.07) (2).
Many other transplant-related factors had slight trends toward
showing a benefit, but failed to achieve statistical significance,
possibly due to low numbers. Given the rarity of the disease, trans-
continental data-sharing collaborations may be required to gather
sufficient numbers to answer some of these questions.
THE ADJUNCTIVE USE OF SEROTHERAPY AND G-CSF
The inclusion of serotherapy (such as anti-thymocyte globulin,
ATG) in a conditioning regimen is often controversial due to
concerns that potential in vivo reduction of alloreactivity may
result in increased relapse rates. However, two randomized trials
in patients undergoing unrelated donor HCT for various malig-
nancies showed no differences in relapse incidence between those
patients who did or did not receive ATG, but did show decreased
rates of GVHD (62, 63). The EWOG–EBMT trial reported no dif-
ference in 5-year RI in patients with JMML undergoing unrelated
donor HCT who did (36%) or did not (33%) receive serotherapy
(P =NS), though there was a trend toward less non-relapse mor-
tality in the serotherapy group (P = 0.08) (1). Most patients who
underwent UCBT in the EUROCORD–CIBMTR study did receive
serotherapy, with no apparent impact on EFS rates (2). Therefore,
at present the current data suggest that the serotherapy should
be utilized for those undergoing unrelated adult HCT or UCBT.
One consideration, however, would be the optimal timing of the
serotherapy for UCBT patients, as some data suggest that earlier
administration is beneficial for preventing excessive in vivo T cell
depletion (61).
Finally, given the intrinsic hypersensitivity of JMML cells to
GM-CSF, it has been questioned whether routine administration
of G-CSF post-HCT to enhance neutrophil recovery would be
associated with an increased risk of relapse. There is no in vitro
data on whether G-CSF directly stimulates JMML stem cells, nor
there is published clinical data on the benefits or risks of G-CSF
in patients with JMML. Since the benefit of post-HCT G-CSF for
patients with AML or CML is unclear, we generally recommend
that it is not given to patients getting BM or PBSC as the stem cell
source, especially in patients with monosomy 7-associated disease
(by analogy to patients with AML) (22). However, until more data
are available, the continued use of G-CSF following UCBT is a
reasonable strategy.
THE GRAFT-vs.-JMML EFFECT
The EWOG–EBMT trial did not show a definitive benefit of either
acute or chronic GVHD for prevention of relapse (1). How-
ever, this analysis may have been confounded by the inclusion
of patients with very high disease burdens at the time of HCT,
in which alloreactive responses may be insufficiently therapeutic.
In the EUROCORD–CIBMTR study, grades II–III acute GVHD
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were associated with a decreased incidence of relapse (P = 0.02),
while grade IV acute GVHD was not surprisingly associated
with high rates of TRM (2). Other small reports have docu-
mented instances of a graft-vs.-JMML effect, including demon-
strations that immunotherapy-based interventions, either rapid
withdrawal of immunosuppression (64, 65), administration of
donor lymphocyte infusions (DLIs) (66–70), and/or immunos-
timulation with interferon-α (71, 72) can result in temporary and
rarely long-lasting disappearance of residual/relapsing JMML cells
following HCT.
In general, immunomanipulation strategies are most effective
in the setting of a low disease burden. In order to accomplish
this post-HCT, when a relapse may be just developing, accu-
rate measurement of minimal disease burden via measurement
of mutated allelic burden will be necessary (47). Preliminary stud-
ies suggest that MRD may be as accurate in peripheral blood as
in bone marrow, which would significantly increase the ease of
sending frequent measurements (47). Another common approach
for post-HCT management of myeloid malignancies is to increase
alloreactivity in an attempt to achieve 100% donor chimerism
(73). However, it is not clear that 100% donor chimerism is
required for all patients with JMML. It has been shown that many
patients with CBL-mutated JMML are long-term survivors with
mixed whole blood chimerism (18), and rare anecdotal cases exist
for other molecular subtypes, including PTPN11 (Christopher C.
Dvorak, personal communication). Ultimately, the combination
of donor chimerism and molecular MRD measurement will likely
prove to be the most accurate method for guiding pre-emptive
immunotherapy.
One drawback to aggressive immunomanipulation is the risk
of causing GVHD in conjunction with the intended graft-vs.-
leukemia (GVL) effect. In the setting of mild to moderate GVHD
development, the clinician is faced with trying to determine
when to treat and how aggressive to be with treatment inten-
sity, so that not too much of the GVL effect is abrogated. In
patients with JMML, in addition to standard corticosteroids,
second line agents could be chosen for their potential role in
simultaneously controlling the JMML itself. Examples include the
mTOR inhibitor sirolimus (74) for acute or chronic GVHD, or
dasatinib (75) for chronic GVHD, both which has been shown
in vitro to directly inhibit growth of some cases of JMML.
Another interesting approach described in one case report is to
utilize 6-mercaptopurine for control of both acute GVHD and
JMML (76).
SECOND TRANSPLANTATION
In the EWOG/EBMT trial, 15 patients underwent second HCT
for treatment of relapsed disease, with the original donor used
most often and TBI being the most common backbone of the
conditioning regimen. A purposeful reduction in GVHD prophy-
laxis led to a high rate of acute GVHD, but at time of publication
almost half of the patients were alive (1). Similar results were seen
in a report from Japan where 5 of 11 patients undergoing sec-
ond HCT were alive at last follow-up (70). Other older reports
confirm the general utility of attempting a second (77) or even
third HCT (78) for recurrent JMML, while a recent case series of
five patients describes a successful cytoreductive approach with
high-dose cytarabine (3 g/m2 q12× 6 doses) plus mitoxantrone
(10 mg/m2/day× 3 days) followed by repeat cell infusion from the
original donor (79). Although the numbers are small, when com-
bined, these results are at least comparable, if not superior, to the
results of second HCT for recurrent acute leukemia (80).
CONCLUSION
Patients with JMML have traditionally been difficult to confidently
diagnose, manage, and transplant. Recent work to decipher the
genetic underpinnings of the disease has significantly improved
our diagnostic capabilities, such that over 90% of patients can
now be molecularly characterized. Not only will this allow for
mutation-specific risk-stratification in the future, but also will
ensure that ongoing and future trials include only patients with
confirmed JMML and not some of its mimics (which might
influence the findings of past reports). Pre-HCT management of
patients with JMML remains primarily symptom-driven, though
advances in understanding of high-risk clinical features will deter-
mine which patients might benefit from pre-HCT chemotherapy.
Furthermore, new techniques to quantify minimal residual dis-
ease burden will allow us to finally determine whether pre-HCT
response to chemotherapy is beneficial for long-term disease-free
survival. HCT for JMML remains problematic, with high relapse
rates regardless of conditioning intensity. An ongoing clinical trial
in the Children’s Oncology Group may determine that less toxic
approaches can be equally effective, thereby shifting the focus to
post-HCT immune manipulation strategies for long-term disease
control. Finally, our increased understanding of the molecular
basis of the disease is beginning to identify possible targets for
selective therapeutic interventions, either pre- or post-HCT, which
ultimately hold the greatest potential for improving the outcomes
of this rare and challenging childhood leukemia.
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